VivoSim Labs (FRA:4OR) Total Stockholders Equity: €3.79 Mil (As of Dec. 2025)


FRA:4OR VivoSim Labs Inc FRA:4OR
38 GF Score
Price €3.49
GF Value €10.31
! 4 Warning Signs
View Full Analysis

What is VivoSim Labs Total Stockholders Equity?

VivoSim Labs FRA:4OR 38 Total Stockholders Equity is €3.79 Mil as of Dec. 2025. GuruFocus rates FRA:4OR with a GF Score™ of 38/100 and a GF Value™ of €10.31. The stock has 4 warning signs investors should review.

VivoSim Labs's Total Stockholders Equity for the quarter that ended in Dec. 2025 was €3.79 Mil. It refers to the net assets owned by shareholders. It does not include minority interest.

Total Stockholders Equity is used to calculate Book Value per Share. VivoSim Labs's Book Value per Share for the quarter that ended in Dec. 2025 was €1.45. The ratio of a company's debt over equity can be used to measure how leveraged this company is. VivoSim Labs's Debt-to-Equity for the quarter that ended in Dec. 2025 was 0.13.

VivoSim Labs  (FRA:4OR) Total Stockholders Equity Explanation

1. Total Stockholders Equity is used to calculate Book Value per Share.

VivoSim Labs's Book Value per Share for the quarter that ended in Dec. 2025 is

Book Value per Share=(Total Stockholders Equity-Preferred Stock)/Shares Outstanding (EOP)
=(3.793-0)/2.608
=1.45

2. The ratio of a company's debt over equity can be used to measure how leveraged this company is.

VivoSim Labs's Debt-to-Equity for the quarter that ended in Dec. 2025 is

Debt-to-Equity=Total Debt / Total Stockholders Equity
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Total Stockholders Equity
=(0.455 + 0.038) / 3.793
=0.13

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

VivoSim Labs Total Stockholders Equity Related Terms

VivoSim Labs Total Stockholders Equity Historical Data

* Premium members only.

The historical data trend for VivoSim Labs's Total Stockholders Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

VivoSim Labs Total Stockholders Equity Chart

VivoSim Labs Annual Data
Trend Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25
Total Stockholders Equity
Get a 7-Day Free Trial Premium Member Only Premium Member Only 32.93 27.43 14.32 3.31 9.71

VivoSim Labs Quarterly Data
Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25
Total Stockholders Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.35 9.71 8.27 6.02 3.79
FRA:4OR
38GF Score
VivoSim Labs Inc FRA:4OR
Total Stockholders Equity is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
What does a Total Stockholders Equity of €3.79 Mil mean?
VivoSim Labs (FRA:4OR) has a Total Stockholders Equity of €3.79 Mil as of Dec. 2025. The total amount of shareholder's equity as recorded on a company's balance sheet. View historical data for VivoSim Labs and its competitors.
Is VivoSim Labs' Total Stockholders Equity too high?
VivoSim Labs' current Total Stockholders Equity is €3.79 Mil. Overall, VivoSim Labs has a GF Score™ of 38/100, reflecting its overall financial health beyond just this single metric.
How does VivoSim Labs' Total Stockholders Equity compare to SLXN and CDT?
VivoSim Labs' Total Stockholders Equity of €3.79 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Stockholders Equity for a Biotechnology company?
A good Total Stockholders Equity depends on the Biotechnology industry context. However, Total Stockholders Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Stockholders Equity mean?
A high Total Stockholders Equity can signal that a stock is expensive relative to its fundamentals. The total amount of shareholder's equity as recorded on a company's balance sheet. View historical data for VivoSim Labs and its competitors. VivoSim Labs's current Total Stockholders Equity is €3.79 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is VivoSim Labs stock overvalued right now?
VivoSim Labs (FRA:4OR) has a current Total Stockholders Equity of €3.79 Mil. The stock's GF Value™ is €10.31, compared to a current price of €3.49 — trading 66.1% below its estimated fair value. The current Total Stockholders Equity is €3.79 Mil. VivoSim Labs' overall GF Score™ is 38/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Stockholders Equity calculated?
Total Stockholders Equity is calculated from a company's financial statements. For VivoSim Labs (FRA:4OR), the current Total Stockholders Equity is €3.79 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is VivoSim Labs (FRA:4OR) Overvalued in 2026?

Based on GuruFocus' analysis, VivoSim Labs stock appears to be undervalued. The current stock price of €3.49 is trading 66.1% below its estimated GF Value™ of €10.31.

Key valuation signals for FRA:4OR:

  • Total Stockholders Equity: €3.79 Mil
  • GF Value™: €10.31 vs. price of €3.49 (66.1% below fair value)
  • GF Score™: 38/100 with 4 warning signs

No single metric tells the full story. See the FRA:4OR stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

VivoSim Labs Business Description

Other Exchanges VIVS:USA
Address 11555 Sorrento Valley road, Suite 100, San Diego, CA, USA, 92121
VivoSim Labs Inc formerly, Organovo Holdings Inc is a biotechnology company focused on developing FXR314 in inflammatory bowel disease (IBD), including ulcerative colitis (UC), based on demonstration of clinical promise in three-dimensional (3D) human tissues as well as preclinical data. FXR is a mediator of gastrointestinal and liver diseases. It is now offering liver toxicology predictive screening and research services as well as working on predicting and studying the intestinal side effect profiles of drugs that are therapeutic candidates of pharmaceutical and biotech companies at all stages of drug development.
38GF Score

Get the complete analysis for FRA:4OR

Total Stockholders Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€3.49
Price
€10.31
GF Value